Breaking AI & Tech News Analyzed

Brazilian President Luiz Inácio Lula da Silva used his Friday social‑media post to herald a new security partnership with the United States as a breakthrough in the fight against transnational crime.The agreement links the Brazilian Federal Revenue Service with U.S. Customs and Border Protection, establishing the DESARMA programme. Under DESARMA the two agencies will exchange real‑time data, apply rigorous cargo‑tracking protocols and launch joint operations to intercept illicit shipments of arms and narcotics.Finance Minister Dario Durigan called the collaboration an “important step in strengthening international cooperation”, noting that it will integrate intelligence and joint actions to curb the flow of weapons and drugs between the two nations.The pact is part of President Donald Trump’s broader “Shield of the Americas” initiative, which seeks to enlist right‑wing governments across the Western Hemisphere in a hard‑line campaign against criminal networks.Despite the cooperation, Lula’s administration has pushed back against Washington’s attempts to label Brazilian gangs such as the Primeiro Comando da Capital (PCC) and Comando Vermelho (CV) as foreign terrorist organisations. Lula and Foreign Minister Mauro Vieira have repeatedly asserted Brazil’s sovereignty and warned against external “tutelage”.In the last twelve months Brazil reported seizing 1,168 illegally imported weapons and parts, most of which originated from the U.S. state of Florida, underscoring the scale of the smuggling problem.A statement from the Revenue Service emphasized that the deal will ensure a “continuous flow of information from U.S. authorities to their Brazilian counterparts”, enhancing operational coordination.Relations remain strained: Vieira told U.S. Secretary of State Marco Rubio that Brazil opposes the terrorist‑label designation, while the Trump administration continues aggressive actions in the region, including lethal strikes on maritime vessels and a controversial raid in Venezuela.Looking ahead, Lula is expected to travel to Washington, D.C., later this year for talks with Trump, providing a diplomatic channel to manage both cooperation and disagreement.

The UK medicines regulator has opened an inquiry into a growing number of clinics that sell injectable peptides while promoting them as cures for everything from ageing to injury recovery. The investigation, disclosed by the Guardian, focuses on whether these businesses are breaching the Human Medicines Regulations 2012 by making unauthorised medicinal claims. Interest in peptide‑based treatments has surged in recent years, driven by social‑media influencers, some healthcare professionals, and direct‑to‑consumer marketers. Yet the scientific foundation for most of these claims is weak, with the bulk of research confined to animal models or cell‑culture studies. According to an MHRA spokesperson, any clinic that advertises a peptide as having therapeutic benefits must treat the product as a medicine, which triggers a comprehensive regulatory framework. "If clinics offering peptide injections make medicinal claims for those treatments, the products will be considered medicines and subject to regulation," the agency warned, adding that it will act against any identified breaches. Guardian reporters identified several high‑ranking Google search results that list peptides such as Cortexin (promoted for neuroprotection), BPC‑157 (claimed to aid tissue repair), and Thymosin Alpha (advertised to boost immunity). After being contacted, one clinic removed the statements from its website. Another clinic, while acknowledging the limited human evidence, continued to market seven specific peptides, providing price lists (£350 per month for a single peptide, £450 for two) and offering delivery via vials, syringes, or pre‑filled pens for an additional fee. During a free consultation, a clinician highlighted the experimental nature of the products, noting the absence of large‑scale, randomised clinical trials and recommending a break of four to eight weeks between treatment cycles to mitigate unknown risks. The clinician suggested BPC‑157 for post‑exercise recovery, describing it as a facilitator of cellular repair and blood flow, but warned against its use in smokers or individuals with a family history of cancer due to potential angiogenic effects. The second peptide discussed was MOTS‑C, portrayed as a mitochondrial enhancer that could improve stress resilience, lower insulin resistance, and reduce visceral fat by boosting cellular energy production (ATP). The MHRA confirmed it is reviewing whether the clinician’s statements constitute medicinal claims. The clinic defended its approach, emphasizing that it clearly informs clients that the peptides are not licensed medicines and that the evidence base is largely pre‑clinical. In a broader statement, Lynda Scammell, head of borderline products at the MHRA, explained that peptide products may be marketed as cosmetics, supplements, or medicines, and each case is assessed on its intended use, pharmacological effect, and supporting evidence. She added, "We disregard claims that products are for ‘research purposes’ if it is clear that such claims are being used as an attempt to avoid medicines regulations." Peptides are short chains of amino acids, some of which occur naturally (e.g., insulin). While synthetic peptide analogues like semaglutide and tirzepatide have secured approval for weight‑loss treatments, many of the compounds promoted by these clinics remain experimental and lack the rigorous safety and efficacy testing required for medicinal products.

Washington, D.C. – In a historic session, the United States Supreme Court examined the Trump administration’s bid to curtail the long‑standing practice of granting citizenship to anyone born on American soil. The hearing drew a sizable crowd of civil‑rights and immigration advocates who decried the proposal as unconstitutional. Lawyers representing the administration argued that the 14th Amendment has been misread for over a century and that citizenship should be limited to children of parents who are legally domiciled in the United States. They contended that the phrase “subject to the jurisdiction thereof” permits the exclusion of infants born to undocumented or temporary‑status parents. Opposing counsel from the ACLU and other groups countered that the amendment’s language, reinforced by the 1898 United States v. Wong Kim Ark decision and the 1952 Immigration and Nationality Act, unequivocally guarantees citizenship regardless of parental status. “The rule was enshrined in the 14th Amendment to keep it out of reach of any official who might try to destroy it,” ACLU attorney Cecillia Wang said. The proceedings were underscored by President Donald Trump’s unprecedented presence in the courtroom, making him the first sitting president to attend Supreme Court oral arguments. Trump left the hearing abruptly, later posting on Truth Social that the United States is “the only country in the world stupid enough to allow ‘birthright’ citizenship.” Protesters such as 21‑year‑old Luis Villaguzman of LULAC expressed personal stakes, noting that the policy would strip benefits from pregnant immigrant mothers and jeopardize their children’s future. “This hits close to home,” he said. Justices probed the administration’s claims, with Justice Kentanji Brown Jackson asking, “Who is domiciled?” while Justice Samuel Alito highlighted the repeated references to “domicile” in the Wong Kim Ark opinion. Justice Brett Kavanaugh questioned why Congress had not clarified the citizenship scope in the 1952 statute, and Justice Amy Coney Barrett warned of the logistical chaos the order could create. Legal scholars warned that the executive order could affect roughly 255,000 infants annually, according to a joint analysis by the Migration Policy Institute and Penn State’s Population Research Institute, potentially creating a “self‑perpetuating, multigenerational underclass.” Outside the court, immigration advocates emphasized the broader implications: the measure could disenfranchise hundreds of thousands of children, many of Latino heritage, and compound the administration’s aggressive deportation agenda. The Court has not set a date for a final ruling, but the hearing offered a glimpse into the judicial scrutiny the case will face as the nation watches a potential reshaping of a core constitutional right.

Unilever, the maker of Marmite and Hellmann's mayonnaise, has agreed to a $44.8 billion deal to combine its food business with US-based McCormick. The deal, which is forecast to result in $600 million of annual cost savings by the end of the third year, will give Unilever majority control of the new company.Under the agreement, McCormick will pay Unilever $15.7 billion in cash and the equivalent of $29.1 billion in shares for most of Unilever's food arm. The new company will combine brands such as Knorr and Pot Noodle with McCormick's condiments and spices, including French's mustard and Cholula hot sauce.Unilever will control 65% of the new spin-off, while McCormick executives will lead the combined company. The deal marks the end of nearly a century of Unilever selling food products in competition against big rivals such as Kraft Heinz, Nestlé, and PepsiCo.The remainder of Unilever, valued at about £100 billion, will focus on beauty, personal care, and home products, repositioning it to compete directly with large household and personal care companies including L'Oréal, Beiersdorf, and Estée Lauder.